William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating.
Stocks · News reference
Palvella Therapeutics Announces Completion Of Rolling NDA Submission To FDA For QTORIN Rapamycin In Microcystic Lymphatic Malformations Under 505(b)(2) Pathway; FDA Filing Decision Expected Within 60 Days
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for CRBG, MTN, CRM and FSLR, while cutting targets for PVLA, SPOT and AMZN; CRM and FSLR were upgraded.
Palvella Says QTORIN Rapamycin Systemic Exposure At Least 40-Fold Lower Than Published Oral Sirolimus Data In Phase 3 Substudy
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.